All Blogs

Jun 11, 2026

Sibel Health Received EU MDR Class IIb CE Mark for ANNE® One: The First Wireless Wearable Patient Monitoring Platform Certified to Key Interoperability Standards (Regulatory Update) On 10 June 2026, Sibel Health Inc., an award-winning medical technology company, announced that its ANNE® One system had receiv...

Jun 12, 2026

Pfizer's USD 10.5 billion partnership with Innovent Biologics is not just another oncology deal; it is a strategic masterstroke in Pfizer's bid to dominate cancer therapy. In May 2026, Pfizer and Innovent announced a global collaboration covering 12 early-stage and de novo oncology programs, including next-generati...

Jun 10, 2026

The life sciences industry is in the midst of a quiet revolution, one that is unfolding not in sprawling clinical trial sites or blockbuster FDA approvals, but inside compact laboratory incubators where miniature, self-organizing replicas of human organs are being grown, monitored, and analyzed at unprecedented sca...

Jun 09, 2026

Roche and Nurix Therapeutics Partner to Advance BTK Degrader Bexobrutideg Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to jointly develop and commercialize bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. Through this pa...

Jun 08, 2026

Summary HR+/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM.  High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinale...

Jun 05, 2026

OrthAlign, Inc. Received FDA 510(k) clearance for the Lantern® ASC system On 03 June 2026, OrthAlign, Inc., a developer of handheld orthopedic navigation technologies, announced that it had received FDA 510(k) clearance for its Lantern ASC system, a navigation solution designed to provide the accuracy of advance...

Jun 05, 2026

Summary The EGFR-mutant NSCLC treatment market was valued at USD 6.6 billion in 2025 and is projected to grow at a 7.3% CAGR over the next decade, driven largely by the emergence of targeted biologics and ADCs. The recent approval of Dato-DXd marks a major milestone and is expected to accelerate the adoption...

Jun 03, 2026

It costs, on average, $2.6 billion and over a decade to bring a single drug to market. Roughly 90% of drug candidates fail in clinical trials. And yet, the pressure to innovate faster, spend smarter, and outmanoeuvre competitors has never been more intense. Molecular modelling isn't just a scientist's tool anymore....

Jun 02, 2026

Hanmi Pharmaceutical Secures Licensing Agreement with Eli Lilly and Company for Sonefpeglutide  Hanmi Pharmaceutical announced a licensing agreement with Eli Lilly and Company covering the development, manufacturing, and commercialization of sonefpeglutide (LAPSGLP-2 analog), Hanmi’s investigational biologi...

Jun 01, 2026

Summary In May 2026, the FDA approved AstraZeneca's BAXFENDY (baxdrostat), the world's first aldosterone synthase inhibitor (ASI), marking the arrival of an entirely new pharmacological class for a condition that affects 1.4 billion people globally. The approval addresses a stubborn clinical gap. Despite exi...